Gene therapy maker Sarepta tells FDA it won't halt shipments despite patient deaths
The highly unusual move is a latest in a string of events that have hammered the company's stock for weeks and recently forced it to lay off 500 employees. The company's decision not to comply with the FDA also places future availability of its leading therapy, called Elevidys, in doubt.
The FDA said in a statement Friday night that officials met with Sarepta and requested it suspend all sales but 'the company refused to do so.' The agency has the authority to pull drugs from the market, but the cumbersome regulatory process can take months or even years. Instead, the agency usually makes an informal request and companies almost always comply.
'We believe in access to drugs for unmet medical needs but are not afraid to take immediate action when a serious safety signal emerges,' FDA Commissioner Marty Makary said in a statement.
Elevidys is the first gene therapy approved in the U.S. for Duchenne's muscular dystrophy, the fatal muscle-wasting disease that affects males, though it has faced scrutiny since its clearance in 2023. The one-time treatment received accelerated approval against the recommendations of some FDA scientists who doubted its effectiveness.
The FDA granted full approval last year and expanded the therapy's use to patients 4 years and older, including those who can no longer walk. Previously, it was only available for younger patients who were still walking.
Sarepta said Friday that its scientific review showed 'no new or changed safety signals' for younger patients with Duchenne's who have earlier stages of the disease. The company said it plans to keep the drug available for those patients.
'We look forward to continued discussions and sharing of information with FDA,' the company said in a statement.
Sarepta halted shipments last month of the therapy for older boys with Duchenne's, which gradually destroys muscle and skeletal strength, resulting in early death. The move followed the deaths of two teenage boys taking the therapy.
The company also confirmed a third death Friday: a 51-year-old patient who was taking an experimental gene therapy in a trial for a different form of muscular dystrophy. Sarepta said it reported the death to the FDA on June 20. The FDA said Friday it placed that trial on hold.
Sarepta noted that the gene therapy involved in the incident uses 'a different dose and is manufactured using a different process,' than Elevidys.
All three patient deaths were linked to liver injury, a side effect noted in Sarepta's prescribing information.
Earlier this week Sarepta announced it would add a bold warning to drug and lay off a third of its employees. The company did not mention the third patient death in its news release or conference call announcing those changes, sparking pointed criticism from Wall Street analysts.
Company shares fell more than 35% Friday to close at $14.07.
Cambridge, Massachusetts-based Sarepta has received FDA approval for three other Duchenne's drugs since 2016, none of which have been confirmed to work. The company has long been criticized for failing to complete several studies needed to secure full FDA approval of its drugs.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
2 hours ago
- Daily Mail
Early-onset Alzheimer's disease linked to another neurological condition suffered by 8million Americans
People with autism are at a significantly greater risk of developing memory-robbing dementia, experts warn. Researchers presenting at the world's largest dementia conference this week suggested rapidly surging autism spectrum disorder (ASD) could increase the risk of dementia, which affects 9million Americans. In one study of nearly 800,000 people, adults with autism and other intellectual disabilities were up to three times more likely to have signs of cognitive decline and dementia. And even autistic people under 50 were 30 percent more likely to be diagnosed with dementia than their neurotypical peers. Another unveiled study showed nearly one in three autistic adults exhibited at least two signs of cognitive decline, like forgetting a word or wandering at night. Experts in Pennsylvania and Washington DC suggested the increased risk could be due to higher rates of other conditions in people with autism, like depression and diabetes, which have been shown to cause damaging inflammation in the brain. Drugs that block neurotransmitters responsible for memory like bladder drugs and Benadryl may also be to blame, one of the studies suggested. The emerging research comes as one in 31 children in the US now have autism, a staggering increase from about one in 150 in the early 2000s. Experts suspect the surge is due to doctors getting better at detecting the disorder and increased awareness. However, health secretary Robert F Kennedy Jr earlier this year announced a series of studies to hone in on 'environmental toxins' he believes are responsible, including pollution, ultra-processed foods and ultrasound scans. Dr Lindsay Shea, one of the study authors and director of the Policy and Analytics Center at Drexel University's AJ Drexel Autism Institute, said during a conference presentation: 'We see that autistic children have grown up to become mostly autistic adults and now older adults. 'The first generation of autistic adults are now in their 80s and 90s.' Dementia is also on the rise, with experts suspecting it could strike 14million Americans by 2060. In one study presented this week at the Alzheimer's Association International Conference, researchers pulled Medicare and Medicaid claim data from 2017 to 2019 of nearly 800,000 Americans ages 30 and over. Participants were split into four groups: autism, autism plus intellectual disability (fetal alcohol syndrome, for example) or intellectual disability. There were 60,087 people in the autism group, 101,748 with both autism and intellectual disability and 632,607 with only an intellectual disability. They were then compared to about 760,000 adults in the general population. The researchers found 30 percent of adults over 65 with autism were diagnosed with dementia compared to 19 percent in the general population, a 45 percent increased risk. The difference was even greater for people with autism and intellectual disability, as 32 percent of this group developed dementia. Among 50- to 64-year-olds, eight percent of people with autism had dementia compared to five percent of the general population, a 46 percent difference. And people with autism and another intellectual disability were three times more likely to have dementia than neurotypical people. The team also found 1.1 percent of autistic individuals between ages 30 and 49 had dementia compared to 0.8 percent in the general population, a 31 percent difference. Dr Shea said: 'This data supports the idea of both early onset and higher prevalence rates of dementia in these populations.' Another study from George Washington University looked at two samples of 210 independent and 500 dependent autistic adults who reported signs of cognitive decline like trouble recalling tasks or words, impaired judgment or changes in behavior. Caregivers also noted their dependent loved ones wandered at night, avoided initiating conversation and lost track of time. Independent participants were between 42 and 81 years old with an average age of 54. Autistic adults dependent on a caregiver were 18 to 68 years old with an average age of About 30 percent of independent autistic people had two or more signs of cognitive decline while 10 percent of dependent adults had caregivers report at least one sign of impairment. The most common cognitive decline indicators were less interest in activities, everyday thinking problems and judgment issues. Dr Gregory Wallace, study author and associate professor at George Washington University, said: 'That's very high given the average age.' Dr Wallace believes certain medications could be to blame. Nearly two-thirds of adults in the study were taking anticholinergics, drugs that block the neurotransmitter acetylcholine, which is crucial for muscle contractions, memory, learning and other functions. They're used to treat a variety of issues including urinary incontinence, gastrointestinal distress, chronic obstructive pulmonary disease (COPD) and Parkinson's disease, which are all more common in autistic people than the general population. These drugs are also sold over the counter in as Benadryl, Tylenol, Advil PM and Dramamine, among others. It's thought that anticholinergics blocking the neurotransmitter acetylcholine over repeated use could lead to permanent damage to cognitive functions. Autistic people also tend to be more sensitive to medications. The increased dementia risk also may be tied to chronic conditions like depression, diabetes and high blood pressure, which induce harmful inflammation in the brain and damage neurons responsible for memory. Dr Shea said: 'This is particularly noteworthy because all of these diagnoses are more prevalent in autism than they are in the general population. 'We know that autistic adults are often unemployed, often don't have community integration and have high rates of obesity.'
Daily Mail
3 hours ago
- Daily Mail
Health officials warn of outbreak of deadly lung disease in major US city
Health officials in New York have issued a warning following the outbreak of a deadly lung disease in parts of the city. The NYC Health Department is currently investigating a community cluster of five cases of Legionnaires' disease in Central Harlem. The patients are located in neighborhoods with the ZIP codes 10027, 10030, 10035, and 10037. Legionnaires' disease is a severe form of pneumonia that causes lung inflammation, and complications from the disease can be fatal. It is caused by a bacterium, known as Legionella that is primarily spread through the inhalation of contaminated water droplets or aerosols. These contaminated droplets can be released from various water sources, including cooling towers, hot tubs, showers, and decorative fountains. To date, there have been no deaths associated with the cluster of patients reported in New York. The source of the infections is unknown and the Health Department is actively investigating these cases and is sampling and testing water from all cooling tower systems in the area. 'Any New Yorkers with flu-like symptoms should contact a health care provider as soon as possible,' deputy chief medical officer Dr Toni Eyssallenne said in a statement. She added: 'Legionnaires' disease can be effectively treated if diagnosed early. 'But New Yorkers at higher risk, like adults aged 50 and older, those who smoke or have chronic lung conditions should be especially mindful of their symptoms and seek care as soon as symptoms begin.' In general, the CDC reports that cases of Legionnaires' disease have been increasing since the early 2000s, with a peak in 2018. While reported cases dropped during the first year of the Covid-19 pandemic, they rebounded in 2021. From 2015 to 2020, the bacteria Legionella caused 184 disease outbreaks in the US, resulting in 786 illnesses, 544 hospitalizations and 86 deaths. About one in 10 people who become sick will die. There is no recent data for Legionnaires' disease. The odds of death are higher when the disease is contracted in a hospital setting, with at least one in four dying. Early symptoms of Legionnaire's include fever, loss of appetite, headache, lethargy, muscle pain, and diarrhea. The severity can range from a mild cough to fatal pneumonia, and treating infection early with antibiotics is key for survival. Legionella can colonize and grow within complex communities of microorganisms called biofilms that form on surfaces within water systems. Once there, the bacteria seeps into the water and becomes aerosolized. Plumbing systems, especially those associated with warm water, such as hot water tanks and distribution pipes, can also serve as reservoirs for Legionella bacteria to multiply. From there it can contaminate water in pipes. Stagnant or low-flow areas in pipes also foster Legionella growth. Legionella bacteria can multiply significantly in the hot water systems of large buildings like hospitals due to several factors, such as water temperatures below 50 degrees Celsius, areas where water doesn't flow well and collects, the presence of amoebas and other bacteria, and the materials used in the pipes. Earlier this year, one person died and several were hospitalized due to an outbreak of Legionnaires' disease at a senior living facility in Vermont. It originated from the care home's water system. Another recent victim of Legionnaires' was 71-year-old Barbara Kruschwitz from Massachusetts died of the disease in 2023 one week after staying at a resort in New Hampshire. Her husband Henry said she had gone swimming in the hotel's pool and hot tub. He said: 'Her heart had stopped and she couldn't be revived. And - that's about as much as I can say.' Water treatment plants typically use a disinfectant such as chlorine to clean out the potable water system. The most reliable way to determine if your water is contaminated with Legionella is to have it tested by a qualified laboratory. Home testing kits are also available, which involve collecting water samples and sending them to a lab for analysis. Legionnaires' disease is a severe form of pneumonia that causes lung inflammation. It is caused by a bacterium, known as Legionella. Around 500 people in the UK and 6,100 in the US suffer every year. The condition can cause life-threatening complications, including respiratory failure, kidney failure and septic shock, which occurs when blood flow to the vital organs is blocked. Most sufferers become ill by inhaling tiny water droplets from infected sources, such as shower heads, hot tubs, swimming pools or ventilation systems in buildings. Anyone can become infected, however, at-risk people include the elderly, smokers and those with suppressed immune systems, such as chemotherapy patients. Symptoms usually develop between two and 10 days after exposure to the bacteria. Early signs include: Headache Muscle Pain Fever and chills People may then experience: Cough, which may bring up blood Breathlessness Chest pain Nausea, vomiting, or diarrhea Confusion Treatment is antibiotics, usually in hospital, as soon as possible. Prevention involves meticulous cleaning and disinfection of water systems. People can reduce their risk by not smoking as this damages the lungs and makes individuals more susceptible.
The Independent
7 hours ago
- The Independent
Luka Doncic credits his new physique to nutrition and training
Lakers star Luka Doncic has unveiled a significantly more muscular physique, which he attributes to an intense training and diet regimen during the off-season. His transformation was showcased in a Men's Health cover story, where he discussed his commitment to a gluten-free, low-sugar diet and two daily workouts. Fans have reacted enthusiastically to Doncic's new look, widely dubbing it a 'revenge body' following his trade from the Dallas Mavericks to the Los Angeles Lakers in February. The trade, which saw Anthony Davis move to the Mavericks, reportedly stemmed from concerns within the Mavericks organization about Doncic's weight and conditioning. Despite fan backlash, Mavericks general manager Nico Harrison defended his decision to trade Doncic, stating he had 'no regrets' and that the move was in the team's best interest.
